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a b s t r a c t
We examined whether the oral bioavailability of cyclosporin A is controlled primarily by P-
glycoprotein (P-gp) or CYP3A in the small intestine. In situ loop method was used to evaluate
the uptake of cyclosporin A (40 nmol) at the upper and lower intestine of wild-type and
mdr1a/1b knockout mice treated or not treated with dexamethasone (75 mg/kg/day, 7 days,
i.p.). Expression of CYP3A mRNA in the control group was higher in the upper than the lower
intestine, while that of the multidrug resistance-1a (mdr1a) mRNA was in the opposite order.
Dexamethasone administration potently induced CYP3A andmdr1amRNAs in the lower and
upper intestine, respectively. At 45 min after cyclosporin A administration into an upper
intestinal loop of the control group of wild-type mice, the ratio of residual cyclosporin A to
dose did not differ significantly from that of mdr1a/1b knockout mice, whereas in dexa-
methasone-treated wild-type mice, the residual ratio was increased significantly. The ratio
of the cyclosporin A metabolite M17 to cyclosporin A in portal venous blood at an upper
intestinal loop of mdr1a/1b knockout mice was much higher than that a lower intestinal
loop. The M17/cyclosporin A ratio of portal venous blood at a lower intestinal loop in mdr1a/
1b knockout mice was increased significantly by dexamethasone treatment. These results
suggest that, under physiological conditions, the oral bioavailability of cyclosporin A is
mainly controlled by CYP3A in the upper intestine, rather than liver, but when P-gp is
induced by steroid, the intestinal absorption of cyclosporin A may be inhibited.
# 2006 Published by Elsevier Inc.
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107intestinal P-gp, rather than intestinal CYP3A, plays a key role
in the interpatient variation in oral bioavailability of cyclos-
porin A. On the other hand, CYP3A accounts for about 30 and
70% of total CYP activity in the liver and small intestine,
respectively [12–14], and intestinal first-pass metabolism
mediated by CYP3A has been shown to be clinically relevant
for several drugs, including cyclosporin A [15,16]. However, it
remains to be fully clarified whether P-gp and/or CYP3A
controls the oral bioavailability of cyclosporin A by limiting
absorption from the small intestine.
We have reported that the blood concentrations of
cyclosporin A [17] and tacrolimus [18] were decreased by
combined steroid hormones due to induction of P-gp and/or
CYP3A in the liver and small intestine. Hsiu et al. [19] also
suggested that quercetin significantly decreased the oral
bioavailability of cyclosporin A by inducing P-gp and/or
CYP3A4. Further, Konishi et al. [20] demonstrated that the
oral bioavailability of cyclosporin A is decreased by
methylprednisolone, and the mechanism involves enhance-
ment of small-intestinal P-gp function. Based on a study
comparing the effects of high-dose dexamethasone (75 mg/
kg/day intraperitoneally, for 7 days) in mdr1a/1b knockout
mice and wild-type mice, we concluded that P-gp plays only
a small role in the absorption of cyclosporin A under
physiological conditions, but after induction by dexametha-
sone, P-gp functions as an absorption barrier to cyclosporin
A in the small intestine [21]. In the present study, we used
an in situ intestinal loop method to examine in detail the
effects of both P-gp and CYP3A on the absorption of
cyclosporin A from the upper and lower small intestine in


























2. Materials and methods
2.1. Materials
Sandimmun1 injection (cyclosporin A) and dexamethasone
were purchased from Novartis Pharma Co. Ltd. (Tokyo, Japan)
and Wako Pure Chemical Industries (Osaka, Japan), respec-
tively. A cyclosporin A metabolite (M17), was supplied by
Shiseido Co. Ltd. (Tokyo, Japan). Other reagents were
purchased from Sigma Co. (St. Louis, MO).
2.2. Animal preparation
All animal experiments were performed in accordance with
the guidelines of the Institutional Animal Care and Use
Committee of Kanazawa University. Experiments were
performed on male mdr1a/1b knockout mice (body weight
22–27 g, Taconic Farms Inc., NY, USA). We used male FVB/
NJcl mice (body weight 23–26 g, SLC, Hamamatsu, Japan) as
the control wild-type mice. Mice were intraperitoneally
injected daily for 7 days with a corn oil solution of
dexamethasone (75 mg/kg/day). The control mice were
intraperitoneally injected daily for 7 days with corn oil
alone. Mice were fasted for 12 h prior to administration of
cyclosporin A into a small intestinal loop, but water was
freely available.Please cite this article as: Mingji Jin et al., Site-dependent contribution





2.3. In situ absorption experiments
The in situ closed loop experiments were performed according
to Bronner and Yost [22]. Following anesthetization of mice by
intraperitoneal injection of sodium pentobarbital (50 mg/kg,
Sigma Co.), the abdomen was opened by a midline long-
itudinal incision and a 5 cm upper (duodenum, jejunum) or
lower (ileum) segment was isolated on a thermostatically
controlled board at 37 8C. For the upper segment, we used
5 cm of upper small intestine from the pylorus, because the
duodenum of mouse is short. The segment was rinsed with
MES buffer (5 mM KCl, 100 mM NaCl, 10 mM MES, 85 mM
mannitol, 0.01% polyethylene glycol; pH 6.4) warmed to 37 8C.
A 0.4 mL aliquot of MES buffer containing cyclosporin A
(40 nmol) was injected into the closed loop at 1.5 h after the
last administration of dexamethasone. Blood samples (100–
500 mL) were collected from the jugular vein and the portal
vein at 45 min after in situ loop administration [23]. The small
intestine was quickly excised, rinsed well with ice-cold
saline, blotted dry and weighed, then homogenized in ice-
cold saline (10%, w/v). In this study, the initial dose (40 nmol)
of cyclosporin A administered into the closed loop was
corrected for adsorption, which was determined by measur-
ing the amount of cyclosporin A in the loop immediately after
in situ administration, because cyclosporin A is readily
adsorbed on the small intestinal membrane. The ratio of
adsorption to dose was 0.203  0.018 of dose (mean  S.D.,
n = 15).
2.4. Measurement of apparent tissue-to-blood
concentration ratio of M17
mdr1a/1b knockout mice were intravenously or orally admi-
nistered with cyclosporin A (10 mg/kg). Blood samples were
collected at 45 min after the administration from the jugular
vein under light ether anesthesia and stored at 30 8C until
assay. Mice were killed by decapitation, then the intestine and
liver were quickly excised, rinsed well with ice-cold saline,
blotted dry, and weighed.
2.5. Preparation of microsomes and plasma membrane
fraction
For preparation of microsomes, the liver was homogenized in
three volumes of 100 mM Tris–HCl buffer (100 mM KCl, 1 mM
EDTA, pH 7.4). Microsomes were prepared as reported
previously [24] and stored at 80 8C until use. The small
intestine was quickly removed and washed with buffer
containing 2 mM HEPES, 0.9% NaCl and 0.5 mM phenylmethyl-
sulfonyl fluoride (PMSF). Mucosa was scraped off with a slide
glass on ice and homogenized in a buffer containing 300 mM
mannitol, 5 mM EDTA, 5 mM HEPES and 1 mM PMSF (pH 7.1).
The homogenate was centrifuged at 10,000  g for 20 min, and
the supernatant was centrifuged at 105,000  g for 60 min at
4 8C. The pellet was added to the buffer containing 500 mM
KCl, 1 mM EDTA, 2 mM dithiothreithol (DTT) and 50 mM
potassium phosphate buffer (KPB, pH 7.4) and again centri-
fuged at 105,000  g for 60 min at 4 8C. The pellet was added to
the buffer containing 1 mM EDTA, 2 mM DTT and 50 mM KPB
(pH 7.4), then stored at 80 8C until use.s of P-glycoprotein and CYP3A to cyclosporin A absorption, and
armacology (2006), doi:10.1016/j.bcp.2006.07.020.




















































































































For the preparation of plasma membrane, the liver was
homogenized in 10 mM Tris–HCl buffer (pH 7.5) containing
2 mM CaCl2 at 4 8C. The homogenate was centrifuged at
3500  g for 10 min, and the supernatant was then cen-
trifuged at 15,000  g for 30 min. The pellet was washed,
resuspended in 50 mM Tris–HCl buffer (pH 7.2), and twice
centrifuged at 10,000  g for 5 min, then stored at 80 8C
until use. The small intestine was quickly removed and
washed with ice-cold isotonic saline containing 1 mM PMSF.
Mucosa was scraped off with a slide glass on ice and
homogenized in a buffer containing 250 mM sucrose, 50 mM
Tris–HCl (pH 7.4), and 1 mM PMSF. The homogenate
was centrifuged at 3000  g for 10 min, and the supernatant
was again centrifuged at 15,000  g for 30 min. The
pellet was resuspended in 0.5 mL of a buffer containing
50 mM mannitol, 50 mM Tris–HCl (pH 7.4), and 1 mM PMSF,
and stored at 80 8C until use. Protein contents
were measured according to the method of Lowry et al.
[25].
2.6. Measurement of metabolic activity of CYP3A
The microsomal activity of CYP3A was measured in terms of
conversion of cyclosporin A to M17, essentially according to
Arlotto et al. [26]. The reaction solution (180 mL) contained
cyclosporin A (final concentration 1–50 mM) and microsomal
protein (final concentration 1 mg/mL) in 100 mM phosphate
buffer (pH 7.4). It was pre-incubated at 37 8C for 2 min,
then 20 mL of the reaction buffer (5 mM NADP+, 50 mM
glucose-6-phosphate, 50 mM MgCl2, and 10 U/mL glucose-6-
phosphate dehydrogenase) was added. The whole was
incubated for 5 min, 100 mL of cold acetonitrile in ice
bath was added, and M17 was measured using high-
performance liquid chromatograpy (HPLC), as described
below.
2.7. Assay of cyclosporin A and its metabolite M17
The assay for cyclosporin A and its metabolite M17 was
performed according to Khoschsorur et al. [27]. Briefly, a
sample of blood or tissue, 1 mL of 0.18N HCl and 4 mL of
diethyl ether were added to a glass tube, but an internal
standard was not used. The tube was shaken vigorously for
5 min. After centrifugation for 5 min at 3000  g, the ether
layer was collected in another glass tube containing 1.25 mL
of 0.1N NaOH. After shaking and centrifugation, the ether
layer was evaporated for 30 min at room temperature. The
residue was reconstituted with 300 mL of mobile phase and a
100 mL aliquot was injected into the HPLC system (LC-9A,
Shimadzu Co. Ltd., Kyoto, Japan). All samples were analyzed
on an HPLC system equipped with a Waters Spherisorb 5 mm
CN column (250 mm  4.6 mm i.d., Waters Co. Ltd., MA). The
absorbance was detected at a wavelength of 210 nm. The
mobile phase consisted of acetonitrile:water (33:67) and was
pumped at a rate of 1.2 mL/min. The limit of quantification for
cyclosporin A and M17 was 30 and 5 ng/mL in 300 mL of
plasma, respectively, and these calibration curves were good
linear (r > 0.98). These coefficients of the variation in the
within-run (n = 5) and the between-run (5 days) precisions
were below 5%.Please cite this article as: Mingji Jin et al., Site-dependent contribution





2.8. Reverse transcription-polymerase chain reaction (RT-
PCR) assay
Total RNA was isolated from the liver and small intestine by
using an Isogen Kit (Wako). Synthesis of cDNA from the
isolated total RNA was carried out using RNase H-reverse
transcriptase (GIBCO BRL, Rockville, MD). Reverse transcrip-
tion (RT) reactions were carried out in 40 mM KCl, 50 mM Tris–
HCl (pH 8.3), 6 mM MgCl2, 1 mM DTT, 1 mM each of dATP,
dCTP, dGTP, and dTTP, 10 units of RNase inhibitor (Promega,
Madison, WI), 100 pmol of random hexamer, total RNA and
200 units of the Moloney murine leukemia virus reverse
transcriptase (Gibco-BRL, Berlin, Germany) in a final volume
of 50 mL at 37 8C for 120 min. Polymerase chain reaction (PCR)
was carried out in a final volume of 20 mL, containing 1 mL of
RT reaction mixture, 50 mM KCl, 20 mM Tris–HCl (pH 8.3),
2.5 mM MgCl2, 0.2 mM each of dATP, dCTP, dGTP, and dTTP,
1 mM each of the mixed oligonucleotide primers, and 1 unit of
Taq DNA polymerase (Gibco-BRL). Reported primers were
used for mouse mdr1a (576 bp) [28], mouse mdr1b (486 bp) [29],
mouse CYP3A (670 bp) [29], and mouse ß-actin (456 bp) [30].
Each cycle consisted of 45 s at 94 8C, 60 s at 60 8C, and 75 s at
72 8C for mdr1a and mdr1b, 45 s at 94 8C, 60 s at 56 8C, and 75 s
at 72 8C for CYP3A, and 45 s at 94 8C, 60 s at 58 8C, and 75 s at
72 8C for ß-actin. The PCR reaction was run for 22 cycles for
mdr1a and ß-actin, for 26 cycles for mdr1b, and for 38 cycles for
CYP3A.
2.9. SDS-PAGE and immunoblotting
SDS-PAGE and immunoblotting with peroxidase/antiperox-
idase staining of the plasma membrane for P-gp and of the
microsomes for CYP3A were carried out essentially as
described by Laemmli [31] and Guengerich et al. [32]. The
amounts of sample protein of liver and small intestine were 4
and 200 mg for CYP3A or 30 and 300 mg for P-gp, respectively.
The sample protein was electrophoresed on 10% sodium
dodecyl sulfate-polyacrylamide gel and transferred onto PVDF
membrane filters (Millipore Co., Billerica, MA). After having
been blocked with 5% skim milk, the filters were incubated
overnight at 4 8C with primary antibody, mouse anti-P-gp C219
(Dako Co., Carpinteria, CA) and rabbit anti-rat CYP3A2 anti-
body (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan), and for
1 h with secondary antibody, anti-mouse IgG HRP-linked
antibody (Cell Signaling, Beverly, MA) and mouse anti-rabbit
IgG-HRP (Santa Cruz Bio., Santa Cruz, CA). Thereafter, the
sample was extensively washed with phosphate-buffered
saline. The immunopositive band was detected by means of a
light-emitting nonradioactive detection system (Amersham
International plc, Little Chalfont, Buckinghamshire, UK) with
Kodak X-Omat R film (Eastman Kodak Co., Rochester, NY).
2.10. Data analysis
The data were analyzed using Student’s t-test to compare the
unpaired mean values of two sets of data. The number of
determinations is noted in each table and figure. A value of
P < 0.05 or 0.01 was taken to indicate a significant difference
between sets of data. The electrophoresis results were




































Fig. 1 – (a and b) Time courses of jugular venous blood concentration (a) and values of the ratio of residual cyclosporin A to
dose (b) after in situ administration of cyclosporin A (40 nmol) into a loop of wild-type mouse upper (*) or lower (4)
intestine or mdr1a/1b knockout mouse upper (*) or lower (~) intestine. Each point and bar represent the meanW S.D. of
four mice. Significantly different from the wild-type mouse upper intestine at yP < 0 .05 and yyP < 0.01, respectively.
Significantly different from the mdr1a/1b knockout mouse upper intestine at *P < 0 .05 and **P < 0.01, respectively.
Significantly different from the wild-type mouse lower intestine at #P < 0 .05 and ##P < 0.01, respectively. (a) CyA in jugular
venous blood and (b) CyA in intestinal loop.R
3. Results
3.1. Site-dependent absorption of cyclosporin A from
intestinal loop after an in situ administration
Fig. 1a shows the time courses of jugular venous blood
concentration of cyclosporin A after administration of
cyclosporin A (40 nmol) into upper and lower intestinal loops
of wild-type andmdr1a/1b knockout mice. When cyclosporin A
was administered into the upper intestine, its concentration
rapidly increased without any significant difference between
the two types of mice. In contrast, after administration of
cyclosporin A into the lower intestine, the blood cyclosporin
A concentration was significantly lower than that after
administration into the upper intestine; moreover, the
cyclosporin A concentration was significantly higher inUN
CO
R
Fig. 2 – The concentrations of cyclosporin A (a) and M17 (b) in po
dose (c) in an upper or lower intestinal loop at 45 min after in situ
lower intestinal loop of wild-type or mdr1a/1b knockout mice w
at 1.5 h after the last administration. Each column and bar repre
*P < 0.05 and **P < 0.01, respectively. (NS) no significant differenc
wild-type with dexamethasone treatment; ( ) mdr1a/1b knocko
knockout with dexamethasone treatment.CT
ED
 
mdr1a/1b knockout mice than in wild-type mice. As shown
in Fig. 1b, the residual amount of cyclosporin A in the
intestinal loop was essentially a mirror image of the change
in the blood concentration, indicating that the absorption of
cyclosporin A was higher in the upper intestine than in the
lower intestine in both types of mice, and that the
absorption from the lower intestine was higher in mdr1a/
1b knockout mice than in wild-type mice.
3.2. Effect of dexamethasone on absorption of cyclosporin
A and its metabolite M17 from intestinal loop after an in situ
administration
Fig. 2 shows the concentrations of cyclosporin A (a) and its
major metabolite M17 (b) in portal venous blood and the ratio
of residual cyclosporin A to dose (c) in upper and lowerrtal venous blood and the ratio of residual cyclosporin A to
administration of cyclosporin A (40 nmol) into an upper or
ith or dexamethasone treatment (75 mg/kg, daily, 7 times),
sent the meanW S.D. of four mice. Significantly different at
e. (&) Wild-type without dexamethasone treatment; ( )


































































Fig. 3 – The value of the M17/cyclosporin A ratio in jugular
or portal venous blood at 45 min after in situ
administration of cyclosporin A (40 nmol) into the upper or
lower intestinal loop of mdr1a/1b knockout mice with ( )
or without ( ) dexamethasone treatment (75 mg/kg, daily,
7 times), at 1.5 h after the last administration. Each column
and bar represent the meanW S.D. of four mice.
Significantly different from the each group of jugular
venous blood at #P < 0.05 and ##P < 0.01, respectively.
Fig. 4 – The values of the apparent tissue-to-blood
concentration ratio (Kb,app) of M17 in the upper intestine,
lower intestine and liver at 45 min after i.v. ( ) or p.o. ( )
administration of cyclosporin A (10 mg/kg) in mdr1a/1b
knockout mice. Each column and bar represent the
meanW S.D. of four mice. **Significantly different from i.v.




intestinal loops at 45 min after in situ administration of
cyclosporin A (40 nmol) in wild-type and mdr1a/1b knockout
mice treated with or without dexamethasone.
There was no significant difference in the portal venous
blood concentrations of cyclosporin A after administration into
the upper intestinal loop between the untreated control groups
of both types of mice, but the concentration after administra-
tion into the lower intestinal loop of mdr1a/1b knockout mice
was significantly higher than that in the case of wild-type mice.
These findings were consistent with the data on jugular venous
blood concentration of cyclosporin A after administration of
cyclosporin A into the intestinal loops (Fig. 1a).
In mice treated with dexamethasone, the blood concentra-
tion of cyclosporin A after administration into the upper
intestinal loop was significantly decreased in wild-type mice,
but was not changed in mdr1a/1b knockout mice. When
cyclosporin A was administered into the lower loop, its blood
concentration was not significantly decreased by dexametha-
sone treatment in both types of mice (Fig. 2a). Fig. 2c shows the
ratio of residual cyclosporin A to the dose in upper and lower
intestinal loops after administration of cyclosporin A. The
dexamethasone treatment significantly increased the residual
ratio of cyclosporin A in the upper intestinal loop of wild-type
mice, but not mdr1a/1b knockout mice. Thus, it appears that
dexamethasone inhibited cyclosporin A absorption from the
upper intestine of wild-type mice, but not P-gp-deficient mice.
As regards the metabolite, the portal venous blood
concentrations of M17 after administration of cyclosporin A
into the upper intestinal loop were similar in both types of
mice; however, dexamethasone treatment significantly
decreased the M17 concentration in wild-type mice, but not
the knockout mice. In the case of administration into the lower
intestinal loop, the blood concentrations of M17 in both types
of mice were very much lower than those after administration
into the upper intestinal loop, and were significantly increased
by dexamethasone treatment (Fig. 2b).
Fig. 3 shows the values of the concentration ratio of M17 to
cyclosporin A in jugular and portal venous blood at 45 min
after administration of cyclosporin A (40 nmol) into the small
intestine loop in mdr1a/1b knockout mice treated with or
without dexamethasone. After administration into the upper
intestinal loop, there was no significant difference between
the values of the M17/cyclosporin A ratio in the untreated
control group and the dexamethasone group, and in jugular
blood and portal blood. However, after administration into the
lower intestinal loop, the value of the M17/cyclosporin A ratio
of the dexamethasone group was about seven times larger
than that in the untreated control group in both jugular and
portal blood. The M17/cyclosporin A ratios in portal blood were
significantly higher than those in jugular blood in both groups.
3.3. Apparent tissue-to-blood concentration ratio of M17
in small intestine and liver after intravenous or oral
administration of cyclosporin A
Fig. 4 shows the values of the apparent tissue-to-blood
concentration ratio (Kb,app) of M17 for the upper small
intestine, lower small intestine and liver ofmdr1a/1b knockout
mice at 45 min after an intravenous or oral administration of
cyclosporin A (10 mg/kg).Please cite this article as: Mingji Jin et al., Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and
effect of dexamethasone in small intestine of mice, Biochemical Pharmacology (2006), doi:10.1016/j.bcp.2006.07.020.













































374There was no difference between theKb,app values of M17 for
the upper and lower intestine after intravenous administration,
but the Kb,app value for the upper intestine after oral admin-
istration was very much higher than that after intravenous
administration, while that for the lower intestine was very
much lower. There was no difference between theKb,app values
for the liver after intravenous and oral administrations, but the
value after intravenous administration was about two to three
times higher than those of the two regions of small intestine.
The tissue concentration of unchanged cyclosporin A was not
evaluated, because of the high tissue adsorption of the drug in
the small intestine after oral administration.
3.4. Expression of P-gp and CYP3A in small intestine and
liver
Fig. 5 shows the results of quantitation of RT-PCR mdr1a,
mdr1bandCYP3AmRNAs in the upper and lower intestine and
liver in wild-type andmdr1a/1b knockout mice treated with or
without dexamethasone. In the untreated wild-type group,
the expression ofmdr1amRNA was less in the upper intestine
than in the lower intestine, while that of mdr1b mRNA was in
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effect of dexamethasone in small intestine of mice, Biochemical Ph
Fig. 5 – (a and b) Effects of dexamethasone on the expression of
intestine and liver of wild-type and mdr1a/1b knockout mice w
last dexamethasone treatment. (a) Mice were given successive
times). The sizes of the reverse transcriptase-polymerase chain
(mdr1b), and 670 bp (CYP3A). Lanes 1–3: no treatment; lanes 4–6: d
and CYP3AmRNAs of wild-type andmdr1a/1b knockout mice wi
bar represent themean W S.D. of threemice. Significantly differe
**P < 0.01, respectively. (&) Wild-type without dexamethasone t




mRNA in the lower intestine and the liver of wild-type mice
were much lower than those of mdr1a mRNA, and the
influence of dexamethasone treatment on the expression
ofmdr1bmRNA could not be observed clearly. Treatment with
dexamethasone clearly altered the expression of mdr1a
mRNA in the upper intestine. The expression of CYP3AmRNA
in the untreated group of wild-type and knockout mice was
higher in the upper intestine than in the lower intestine.
Dexamethasone induced CYP3A mRNA expression more
strongly in the lower intestine than in the upper intestine.
Dexamethasone also induced mdr1a and CYP3A mRNA
expression in the liver. The expression levels of P-gp and
CYP3A proteins and the effect of dexamethasone were
confirmed by Western blot analysis using tissues of wild-
type mice (Fig. 6). The protein levels of P-gp in the upper
intestine and liver were elevated to about four and three times
the untreated control level by dexamethasone treatment,
respectively, but the level in the lower intestine was hardly
changed by dexamethasone. On the other hand, the protein
levels of CYP3A in the lower intestine and liver were elevated
to about five and two times the control level by dexametha-
sone treatment, respectively, while the level in the upper
intestine was little elevated.CT
ED
s of P-glycoprotein and CYP3A to cyclosporin A absorption, and
armacology (2006), doi:10.1016/j.bcp.2006.07.020.
mdr1a, mdr1b and CYP3A mRNAs in upper intestine, lower
ith or without dexamethasone treatment, at 1.5 h after the
i.p. administrations of dexamethasone (75 mg/kg, daily, 7
reaction (RT-PCR) products are 576 bp (mdr1a), 486 bp
examethasone treatment. (b) Relative expression ofmdr1a
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Fig. 6 – Western blot analysis of P-gp (a) and CYP3A (b) proteins in the upper intestine, lower intestine and liver of wild-type
mice with or without dexamethasone treatment, at 1.5 h after the last dexamethasone treatment. Mice were given
successive i.p. administrations of dexamethasone (75 mg/kg, daily, 7 times). Lanes 1–3: no treatment; lanes 4–6:
dexamethasone treatment.
Fig. 7 – (a–c) Enzyme activity of microsomal formation of M17 from cyclosporin A. Microsomes were obtained from isolated
small intestine of wild-type mice (a), small intestine of mdr1a/1b knockout mice (b) and liver (c) of wild-type and mdr1a/1b
knockout mice with (closed symbol) or without (open symbol) dexamethasone treatment (75 mg/kg, daily, 7 times), at 1.5 h
after the last administration. Each symbol represents the meanW S.D. of four mice. (a and b) (*) Upper intestine; (4) lower
intestine; (c) (*) wild-type mice; (4) mdr1a/1b knockout mice.UN
CO
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E3.5. Enzyme activity of CYP3A in small intestine and liver
Fig. 7 shows the activity for in vitro formation of M17 from
cyclosporin A in microsome preparations from the small
intestine and liver of wild-type and mdr1a/1b knockout mice
treated with or without dexamethasone. There was little
difference in the activity of the small intestine or liver between
untreated wild-type and mdr1a/1b knockout mice. However,
the activities in the upper intestine of both types of mice were
much higher than those in the lower intestine. Further, the
activities in the liver of both types of untreated mice were
about 20 times higher than those in the upper intestine.
Dexamethasone treatment increased the activities in the
upper intestine and liver of both types of mice by about 3- and
25-fold, respectively. Further, dexamethasone treatment
increased the activities in the lower intestine, which almost
lacked metabolic activity in untreated mice, to the levels seen







We previously suggested that P-gp had little influence on the
intestinal absorption of cyclosporin A under physiological
conditions, whereas after induction by dexamethasone, itPlease cite this article as: Mingji Jin et al., Site-dependent contribution
effect of dexamethasone in small intestine of mice, Biochemical Phmarkedly inhibited the oral bioavailability in mice; however,
the contribution of CYP3A to the intestinal absorption was
not evaluated [21]. In that study, we found that the magnitude
of mdr1a mRNA was in the order of ileum > jejunum
> duodenum, while that of CYP3A mRNA was in the opposite
order; further, of cyclosporin A under physiological condi-
tions, whereas after induction by dexamethasone induced
these mRNAs more strongly in the intestinal regions where
expression was weaker in untreated animals. Thorn et al. [33]
reported regarding the expression of CYP and mdr mRNAs
along the human gastrointestinal tract. Then, the pattern of
expression of these mRNAs in duodenum, jejunum and ileum
of human was well similar to those of our mice.
In the present study, in order to clarify the intestinal site-
specific roles and functions of P-gp and the cyclosporin A-
metabolizing enzyme CYP3A in cyclosporin A absorption, we
firstly confirmed that the expression of P-gp and CYP3A at the
mRNA and protein levels in the upper and lower small
intestine is fundamentally the same as the above-described
results (Figs. 5 and 6).
Yamaguchi et al. reported that the intestinal secretion of
grepafloxacin in mdr1a/1b knockout mice is decreased to 62%
of that in wild-type mice, and pre-administration of cyclos-
porin A to wild-type mice resulted in comparable secretion to
that in mdr1a/1b knockout mice with or without cyclosporin As of P-glycoprotein and CYP3A to cyclosporin A absorption, and
armacology (2006), doi:10.1016/j.bcp.2006.07.020.


























































































































pre-administration [34]. The ratio of intestinal secretion to
dose of grepafloxacin in both types of mice was in the range of
5–7%. Similarly, we found that the values of the ratio of
intestinal secretion of cyclosporin A to dose over 45 min after
an i.v. administration of cyclosporin A (10 mg/kg) in wild-type
and mdr1a/1b knockout mice were 0.8  0.2 and 0.6  0.2%
(mean  S.D., n = 4), respectively. Therefore, we considered
that the intestinal secretion of cyclosporin A is negligible in
the context of this intestinal loop study.
We have shown here that (1) the absorption of cyclosporin
A from the upper intestine is very much higher than that from
the lower intestine; (2) in the upper intestine, there is no
significant difference in absorption of cyclosporin A between
wild-type and mdr1a/1b knockout mice, whereas in the lower
intestine, absorption of cyclosporin A in mdr1a/1b knockout
mice was higher than that of wild-type mice; (3) dexametha-
sone treatment inhibited the absorption of cyclosporin A from
the upper intestine, but not from the lower intestine, in wild-
type mice; (4) the blood concentration of the major metabolite
M17 was higher after administration of cyclosporin A into the
upper intestine than into the lower intestine and (5) the blood
concentration of M17 was lowered by dexamethasone after
administration of cyclosporin A into the upper intestine in
wild-type mice, but not mdr1a/1b knockout mice, whereas it
was increased by dexamethasone after administration of
cyclosporin A into the lower intestine in both types of mice
(Figs. 1 and 2). Furthermore, P-gp was expressed more strongly
in the lower intestine than in the upper intestine at both the
mRNA and protein levels, and the protein level in the upper
intestine was strongly induced by cyclosporin A under
physiological conditions, whereas after induction by dexa-
methasone. In contrast, CYP3A was expressed more strongly
in the upper intestine than in the lower intestine in terms of
both protein level and metabolic activity, and it was more
strongly induced by dexamethasone in the lower intestine
than in the upper intestine. These findings represent a
significant extension of our previous study [21], and we
confirmed that cyclosporin A was absorbed predominantly
from the upper intestine in mice, as reported by Cakaloglu
et al. [35].
It is well known that the major metabolite of cyclosporin A is
M17, rather than M1 or M21, which are generated by CYP3A in
intestinal or hepatic microsomes [36,37]. Cyclosporin A may be
metabolized to M17 during transport in mucosal epithelial cells
of upper intestine (Figs. 2 and 4). Although the cyclosporin A-
metabolizing activity in the upper intestine is only about one-
thirdofthatintheliver, theactivityisincreasedtothelevel inthe
liverbydexamethasonetreatment(Fig.7).Afterdexamethasone
treatment, the formation of M17 was significantly increased in
the lower intestine (Fig. 2c). Moreover, it is suggested that
cyclosporin A is extensively metabolized to M17 in the small
intestine rather than in the liver after oral administration of
cyclosporinA,since the ratio ofM17/cyclosporinA washigher in
portal blood than in jugular blood, irrespective of dexametha-
sone treatment and administration route (Fig. 3). We consider
that cyclosporin A undergoes a first-pass effect from CYP3A in
the upper intestine, rather than in the liver.
mdr1a/1b knockout mice have similar CYP3A activity, but
are deficient in P-gp, compared with the wild-type mice.
Schuetz et al. [38] has been reported that CYP3A catalyticPlease cite this article as: Mingji Jin et al., Site-dependent contribution





activity measured as midazolam 10- and 4-hydroxylation in
liver microsomes from these knockout mice revealed a rank
order of activities with mdr1a/1b(/) >mdr1a(/) >
mdr1b(/) >mdr1a/1b(+/+). But we evaluated the CYP3A
activity by microsomal formation of M17 from cyclosporine A.
However, when cyclosporin A was orally administered, the
bioavailability in mdr1a/1b knockout mice was not different
from that in wild-type mice. Thus, we concluded that P-gp
plays only a small role in the intestinal absorption of
cyclosporin A under physiological conditions [21]. In the
present study, after administration of cyclosporin A into the
regional intestinal loops, the blood concentrations of cyclos-
porin A and metabolite M17 were similar inmdr1a/1b knockout
mice and wild-type mice, except that the blood concentration
of cyclosporin A after administration into the lower intestine
was higher in mdr1a/1b knockout mice than in wild-type mice
(Fig. 2a). This may be due to lack of the absorption barrier
function of P-gp in mdr1a/1b knockout mice, although the
lower intestine is only a minor absorption site of cyclosporin
A. After dexamethasone treatment, P-gp significantly affected
the bioavailability of cyclosporin A [21], because of strong
induction of P-gp in the upper intestine. As shown in Fig. 2b,
dexamethasone treatment lowered the blood concentration of
M17 after administration of cyclosporin A into the upper
intestinal loop of wild-type mice. This suggests that M17 is
also a substrate of P-gp. Therefore, there may be complex
interactions among intact cyclosporin A, its metabolites, P-gp,
and metabolizing enzymes at the absorption sites.
In conclusion, we have confirmed that cyclosporin A is
absorbed predominantly from the upper intestine in mice.
CYP3A and P-gp are highly expressed and function predomi-
nantly in the upper intestine and the lower intestine,
respectively, but are strongly induced by high-dose steroid
hormone at the sites where their expression is weak in
untreated animals. Therefore, the oral bioavailability of
cyclosporin A is primarily controlled by CYP3A in the upper
small intestine of mice under physiological conditions, whereas
after treatment with inducers, P-gp in the upper intestine also
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